PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma

Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system

(2016) Taek-Chin Cheong et al.   Nature Communications

CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma

(2015) M. E. Olanich et al.   CLINICAL CANCER RESEARCH

Improved vectors and genome-wide libraries for CRISPR screening

(2014) Neville E Sanjana et al.   NATURE METHODS

A call to ARMS: targeting thePAX3-FOXO1gene in alveolar rhabdomyosarcoma

(2013) Mary E Olanich et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells

(2013) Ophir Shalem et al.   SCIENCE

Mechanisms and insights into drug resistance in cancer

(2013) Hiba Zahreddine et al.   Frontiers in Pharmacology

ERG Transcription Factor as an Immunohistochemical Marker for Vascular Endothelial Tumors and Prostatic Carcinoma

(2011) Markku Miettinen et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Antitumor Activity of Sustained N-Myc Reduction in Rhabdomyosarcomas and Transcriptional Block by Antigene Therapy

(2011) R. Tonelli et al.   CLINICAL CANCER RESEARCH

Genome-Wide Identification of PAX3-FKHR Binding Sites in Rhabdomyosarcoma Reveals Candidate Target Genes Important for Development and Cancer

(2010) L. Cao et al.   CANCER RESEARCH

High Expression of the PAX3-FKHR Oncoprotein Is Required to Promote Tumorigenesis of Human Myoblasts

(2009) Shujuan J. Xia et al.   AMERICAN JOURNAL OF PATHOLOGY

A Versatile Viral System for Expression and Depletion of Proteins in Mammalian Cells

(2009) Eric Campeau et al.   PLoS One

Defining the Cooperative Genetic Changes That Temporally Drive Alveolar Rhabdomyosarcoma

(2008) S. Naini et al.   CANCER RESEARCH

Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma

(2007) Ken Kikuchi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS